vs
Crown Castle（CCI）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
Crown Castle的季度营收约是Revvity的1.3倍（$1.0B vs $772.1M），Revvity净利率更高（12.7% vs -45.9%，领先58.7%），Revvity同比增速更快（5.9% vs -4.8%），Revvity自由现金流更多（$161.8M vs $-43.0M），过去两年Revvity的营收复合增速更高（9.0% vs -4.5%）
Crown Castle Inc.是总部位于美国得克萨斯州休斯敦的房地产投资信托企业，同时是美国共享通信基础设施服务商，在全球设有100个办事处，旗下拥有超4万座信号塔、约8.5万英里光纤线路，为小基站及光纤系统提供网络支撑。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
CCI vs RVTY — 直观对比
营收规模更大
CCI
是对方的1.3倍
$772.1M
营收增速更快
RVTY
高出10.7%
-4.8%
净利率更高
RVTY
高出58.7%
-45.9%
自由现金流更多
RVTY
多$204.8M
$-43.0M
两年增速更快
RVTY
近两年复合增速
-4.5%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.0B | $772.1M |
| 净利润 | $-464.0M | $98.4M |
| 毛利率 | — | — |
| 营业利润率 | 46.0% | 14.5% |
| 净利率 | -45.9% | 12.7% |
| 营收同比 | -4.8% | 5.9% |
| 净利润同比 | — | 3.9% |
| 每股收益（稀释后） | $1.48 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CCIRVTY
| Q1 26 | $1.0B | — | ||
| Q4 25 | $1.1B | $772.1M | ||
| Q3 25 | $1.1B | $698.9M | ||
| Q2 25 | $1.1B | $720.3M | ||
| Q1 25 | $1.1B | $664.8M | ||
| Q4 24 | $1.1B | $729.4M | ||
| Q3 24 | $1.1B | $684.0M | ||
| Q2 24 | $1.1B | $691.7M |
净利润CCIRVTY
| Q1 26 | $-464.0M | — | ||
| Q4 25 | $294.0M | $98.4M | ||
| Q3 25 | $323.0M | $46.7M | ||
| Q2 25 | $291.0M | $53.9M | ||
| Q1 25 | $-464.0M | $42.2M | ||
| Q4 24 | — | $94.6M | ||
| Q3 24 | $303.0M | $94.4M | ||
| Q2 24 | $251.0M | $55.4M |
毛利率CCIRVTY
| Q1 26 | — | — | ||
| Q4 25 | 97.4% | — | ||
| Q3 25 | 97.2% | 53.6% | ||
| Q2 25 | 97.5% | 54.5% | ||
| Q1 25 | 97.4% | 56.5% | ||
| Q4 24 | 97.7% | — | ||
| Q3 24 | 97.6% | 56.3% | ||
| Q2 24 | 97.7% | 55.7% |
营业利润率CCIRVTY
| Q1 26 | 46.0% | — | ||
| Q4 25 | 48.8% | 14.5% | ||
| Q3 25 | 49.0% | 11.7% | ||
| Q2 25 | 47.7% | 12.6% | ||
| Q1 25 | 49.1% | 10.9% | ||
| Q4 24 | 51.0% | 16.3% | ||
| Q3 24 | 47.5% | 14.3% | ||
| Q2 24 | 44.7% | 12.4% |
净利率CCIRVTY
| Q1 26 | -45.9% | — | ||
| Q4 25 | 27.5% | 12.7% | ||
| Q3 25 | 30.1% | 6.7% | ||
| Q2 25 | 27.5% | 7.5% | ||
| Q1 25 | -43.7% | 6.4% | ||
| Q4 24 | — | 13.0% | ||
| Q3 24 | 27.1% | 13.8% | ||
| Q2 24 | 22.7% | 8.0% |
每股收益（稀释后）CCIRVTY
| Q1 26 | $1.48 | — | ||
| Q4 25 | $0.67 | $0.86 | ||
| Q3 25 | $0.74 | $0.40 | ||
| Q2 25 | $0.67 | $0.46 | ||
| Q1 25 | $-1.07 | $0.35 | ||
| Q4 24 | — | $0.77 | ||
| Q3 24 | $0.70 | $0.77 | ||
| Q2 24 | $0.58 | $0.45 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $55.0M | $919.9M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | — | $7.3B |
| 总资产 | $31.4B | $12.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CCIRVTY
| Q1 26 | $55.0M | — | ||
| Q4 25 | $99.0M | $919.9M | ||
| Q3 25 | $57.0M | $931.4M | ||
| Q2 25 | $94.0M | $991.8M | ||
| Q1 25 | $60.0M | $1.1B | ||
| Q4 24 | $100.0M | $1.2B | ||
| Q3 24 | $194.0M | $1.2B | ||
| Q2 24 | $155.0M | $2.0B |
总债务CCIRVTY
| Q1 26 | — | — | ||
| Q4 25 | $21.6B | — | ||
| Q3 25 | $21.6B | — | ||
| Q2 25 | $22.0B | — | ||
| Q1 25 | $22.9B | — | ||
| Q4 24 | $23.5B | — | ||
| Q3 24 | $23.5B | — | ||
| Q2 24 | $22.9B | — |
股东权益CCIRVTY
| Q1 26 | — | — | ||
| Q4 25 | $-1.6B | $7.3B | ||
| Q3 25 | $-1.5B | $7.4B | ||
| Q2 25 | $-1.4B | $7.6B | ||
| Q1 25 | $-1.3B | $7.6B | ||
| Q4 24 | $-133.0M | $7.7B | ||
| Q3 24 | $5.3B | $7.9B | ||
| Q2 24 | $5.7B | $7.9B |
总资产CCIRVTY
| Q1 26 | $31.4B | — | ||
| Q4 25 | $31.5B | $12.2B | ||
| Q3 25 | $31.5B | $12.1B | ||
| Q2 25 | $31.6B | $12.4B | ||
| Q1 25 | $31.8B | $12.4B | ||
| Q4 24 | $32.7B | $12.4B | ||
| Q3 24 | $38.0B | $12.8B | ||
| Q2 24 | $38.2B | $13.4B |
负债/权益比CCIRVTY
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 4.43× | — | ||
| Q2 24 | 4.04× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $-43.0M | $161.8M |
| 自由现金流率自由现金流/营收 | -4.3% | 21.0% |
| 资本支出强度资本支出/营收 | 1.0% | 2.6% |
| 现金转化率经营现金流/净利润 | — | 1.85× |
| 过去12个月自由现金流最近4个季度 | $4.3B | $509.4M |
8季度趋势，按日历期对齐
经营现金流CCIRVTY
| Q1 26 | — | — | ||
| Q4 25 | $3.1B | $182.0M | ||
| Q3 25 | $714.0M | $138.5M | ||
| Q2 25 | $832.0M | $134.3M | ||
| Q1 25 | $641.0M | $128.2M | ||
| Q4 24 | $2.9B | $174.2M | ||
| Q3 24 | $699.0M | $147.9M | ||
| Q2 24 | $768.0M | $158.6M |
自由现金流CCIRVTY
| Q1 26 | $-43.0M | — | ||
| Q4 25 | $2.9B | $161.8M | ||
| Q3 25 | $671.0M | $120.0M | ||
| Q2 25 | $792.0M | $115.5M | ||
| Q1 25 | $601.0M | $112.2M | ||
| Q4 24 | $2.8B | $149.8M | ||
| Q3 24 | $661.0M | $125.6M | ||
| Q2 24 | $729.0M | $136.6M |
自由现金流率CCIRVTY
| Q1 26 | -4.3% | — | ||
| Q4 25 | 268.4% | 21.0% | ||
| Q3 25 | 62.6% | 17.2% | ||
| Q2 25 | 74.7% | 16.0% | ||
| Q1 25 | 56.6% | 16.9% | ||
| Q4 24 | 247.3% | 20.5% | ||
| Q3 24 | 59.0% | 18.4% | ||
| Q2 24 | 65.9% | 19.7% |
资本支出强度CCIRVTY
| Q1 26 | 1.0% | — | ||
| Q4 25 | 17.0% | 2.6% | ||
| Q3 25 | 4.0% | 2.6% | ||
| Q2 25 | 3.8% | 2.6% | ||
| Q1 25 | 3.8% | 2.4% | ||
| Q4 24 | 15.7% | 3.4% | ||
| Q3 24 | 3.4% | 3.3% | ||
| Q2 24 | 3.5% | 3.2% |
现金转化率CCIRVTY
| Q1 26 | — | — | ||
| Q4 25 | 10.40× | 1.85× | ||
| Q3 25 | 2.21× | 2.97× | ||
| Q2 25 | 2.86× | 2.49× | ||
| Q1 25 | — | 3.03× | ||
| Q4 24 | — | 1.84× | ||
| Q3 24 | 2.31× | 1.57× | ||
| Q2 24 | 3.06× | 2.87× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CCI
| Site rental | $961.0M | 95% |
| Services and other | $49.0M | 5% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
